Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.63 |
| ▸ | NMBR | P28336 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455733 | 0.90 | SIRT2 (0.53) | SIRT2NMBR | |
| SCHEMBL18715386 | 0.87 | SIRT2 (0.67) | SIRT2NMBRMEN1KMT2A | |
| SCHEMBL12626396 | 0.86 | SIRT2 (0.66) | SIRT2NMBRMEN1KMT2A | |
| SCHEMBL30063496 | 0.83 | SIRT2 (0.84) | SIRT2NMBR | |
| SCHEMBL2470124 | 0.82 | SIRT2 (0.64) | SIRT2NMBRMEN1KMT2A | |
| SCHEMBL2470129 | 0.82 | SIRT2 (0.64) | SIRT2NMBRMEN1KMT2A | |
| SCHEMBL4246949 | 0.82 | SIRT2 (0.67) | SIRT2NMBRMEN1KMT2A | |
| SCHEMBL10026711 | 0.82 | SIRT2 (0.64) | SIRT2NMBRMEN1KMT2A | |
| SCHEMBL22356512 | 0.82 | SIRT2 (0.61) | SIRT2NMBR | |
| SCHEMBL2000374 | 0.82 | SIRT2 (0.61) | SIRT2NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970796-B1 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS STABILIZED PACAP PEPTIDE | SENJU PHARMA CO (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-12304932-B2 | PACAP stabilized peptide | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-20220202905-A1 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| EP-3970796-A1 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | Senju Pharmaceutical Co., Ltd. (JP) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304932-B2 | PACAP stabilized peptide | VIP, DNPEP, SCTR | SIRT2 2759/4885NMBR 639/4885POLB 4810/4885 |
| US-20220202905-A1 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | BDNF, NTRK2, NGF | SIRT2 2927/4885NMBR 282/4885POLB 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.